KANAGAWA
Leading Biotech Companies

In Kanagawa, there are many excellent companies that take advantage of abundant and diverse biotechnology resources in the region.

KANAGAWA

Accelerating the innovation along with Kanagawa biotech companies

Kanagawa Prefecture is located in the Greater Tokyo Metropolitan area and is home of 33% of Japan's population and 37% of the national economy. It is an attractive area of continuous development, supported by industries with advanced technical capabilities and a wealth of industrial human resources.
Many technologically advanced bio enterprises and healthcare-related businesses are clustered in Kanagawa Prefecture. The Kanagawa Prefectural Government, Kanagawa Industrial Promotion center (KIP), and the Japan External Trade Organization's Yokohama Trade and Industrial Information center (JETRO Yokohama) are publicizing biotech and healthcare-related companies that are particularly interested in establishing business bases overseas or conducting international business, who have been recommended by municipalities and economic organizations in the prefecture.
This brochure is published in the hope of making these companies' excellent products known extensively and thereby helping them to create new business opportunities and eventually contribute to the further vitalization of Kanagawa's industry and economy.



3D cell culture plate for innovative research

SCIVAX Life Sciences

Company Name	SCIVAX Life Sciences, Inc.
Location	Kawasaki, Kanagawa, Japan
Founded in	June, 2013
Capital	USD 838,000
Representative	Nobutaka Tani
Division	Administration
Name	Atsushi Mizuno
e-mail	atsushi_mizuno@scivaxls.com
Tel	+81-44-580-3008

Our main business is sales and manufacture of original plates, NCP (NanoCulture Plates), for 3D cell culture. NCP is the product that enables cells to be cultured in an environment that better reflects the in-vivo environment than conventional 2D culture. Pharmaceuticals and researchers have valued NCP's biological reproducibility. We also offer contract research services for 3D culture, such as anti-cancer drug screening and hepatocyte toxicity testing.
To provide these products and services, we have just established a research laboratory in Woburn, MA, in Jun 2014. We are strongly promoting our business in the US.

We have a sister company, JSR-N.V., in Belgium. JSR-N.V. is a distributor of NCP in EU.
JSR-N.V. information
Address: Technologielaan 8, B-3001, Leuven, Belgium
Phone: +32-(0)16-832-832; Fax: +32-(0)16-832-839

Desired business for expansion

- Joint research and development
- Product sales
- contract research services

Patent

JP4159103
US7727759
JP2008-501636
PCT/JP2012/072657

Introduction of promoted technologies

NanoCulture Plate (NCP) is a novel technology for 3D cell culture with combined advantages of scaffold-based technologies and ease of use. A bio-mimetic scaffold pattern that mimics structures observed in normal extracellular matrix supports the development of spheroids in a consistent and reproducible manner.
This nano-scale structure micro-fabricated on the bottom film inhibits the adhesion of the cells to the plate, and enhances their migration. Cells seeded on a NCP migrate on the plate and continue adhering with nearby cells, which enables quick formation of large spheroids.

[Strength and characteristics of our technologies]

- Natural and active spheroid
  - ✓Good cell growth, high proliferation
  - ✓Good cell viability
- Scaffold type 3D cell culture with easy handling
  - ✓Ready-to-use
- Easy to observe
  - ✓Transparent flat bottom structure
  - ✓Spheroids adhere to well-bottom film
    - ➢Spheroids can be observed with fixed focal point
    - ➢Compatible with time-lapse imaging

[Collaborative investigation]

- Search target gene by using the 3D culture system
- Target validation by using the 3D culture system
- Screening of lead compound by using the 3D culture system
- Lead optimization by using the 3D culture system

http://www.scivax-usa.com/

Our proteomics expertise for the solutions of various problems in bioscience and medicine

Medical ProteoScope

Company Name	Medical ProteoScope Co., Ltd.
Location	Yokohama, Kanagawa, Japan
Founded in	November, 2002
Capital	USD 500,000
Representative	Yoshihiro Ohtaki

Division	Biomolecule Analysis Group
Name	Takao Kawakami
e-mail	kawakami@medicalproteoscope.com
Tel	+81-45-374-3361

Medical ProteoScope is a company of proteomics excellence that aims to explore the quality of life. Proteomics has been essential in various fields of biological researches. By integrating our state-of-the-art proteomics technology, we are developing protein biomarkers closely related to drug response, progression of disease, and metastatic risk in cancer patients. Our contract researches with pharmaceutical companies have produced promising protein candidates. These biomarkers will lead to improvement of treatment outcomes as well as early detection of diseases. Analytical support for various basic researches is our major activity. We welcome any requests in relation to proteomic analysis.

Desired business for expansion

- Joint research and development
  (Consignment study including biomarker discovery)
- Testing service
  (Proteomic consignment study)

Patent/Monograph

Title: METHOD FOR PREDICTION OF POSTOPERATIVE PROGNOSIS, AND DIAGNOSIS KIT
Application Number: PCT/JP2008/069289
Filing Date: 10/17/2008
WIPO Patent Application: WO/2009/051277
Publication Date: 04/23/2009

Introduction of promoted technologies

Our strength is the analytical platforms covering almost all key proteomic technologies including:

1. Quantitative and differential detection of PTMs including reversible phosphorylation
2. Identification of infinitesimal proteins via immunoprecipitation (IP) assay
3. Proteomic differential analysis of Formalin-fixed paraffin-embedded (FFPE) tissues
4. The software program developed in-house for analysis of a huge volume of measurement data output from mass spectrometry systems

One of our goals in these technology developments is to measure small but biologically significant changes in the proteome concerned. Our business includes contract researches with pharmaceutical companies that need proteomic technologies to solve their topics, e.g. screening candidate proteins for quantitative evaluation of the side effect(s) of compounds under development. Our proteomic technologies will also be useful in the academia.

Contract molecular imaging services

BayBioImaging

Company Name	BayBioImaging.Co.Ltd.
Location	Yokohama, Kanagawa, Japan
Founded in	April, 2006
Capital	USD 333,000
Representative	Tetsu Arisawa

Division	President
Name	Tetsu Arisawa
e-mail	t-arisawa@baybioimaging.com
Tel	+81-45-789-2100

BayBioImaging has established since April, 2006, oriented from Radiology, Medical department of Yokohama City University.
Our main business is contract research services using molecular imaging. Our policy is the "Imaging" potentiality promotes efficiency of clients' research and development of medicine.

Desired business for expansion

- Joint research and development
  (We provide research and development using PET imaging)
- Testing service
  (We provide contract services; labeling with RI or fluorescent, small animal imaging study, and clinical study support related on Radiology)

Introduction of promoted technologies

We provide pre-clinical and clinical study support services;

1) Labeling synthesis with RI or fluorescence

2) Small animal imaging study (PET, in vivo fluorescent imaging, autoradiography) and biodistribution study

3) Support for clinical study using radiopharmaceuticals. BBI assist for any stage of your development of novel medicine by our imaging technique and knowhow

Transporters: Important tool for the development of new drugs

GenoMembrane

Company Name	GenoMembrane Co.,Ltd.
Location	Yokohama, Kanagawa, Japan
Founded in	April, 2002
Capital	USD 387,500
Representative	Kazutaka Muraguchi

Division	Business Development Dept.
Name	Nozomi Mizuno
e-mail	n.mizuno@genomembrane.com
Tel	+81-45-508-2326

Genomembrane Co., Ltd. was established as a bio-tech venture company in April, 2002, by a group of scientists. GenoMembrane's aims are to provide transporter-related products and services that will be useful in the development and design of novel drugs for clinical application. With the progress of research on the function of transporters as drug carriers, it has become increasingly important to take account of their effects at an early stage during drug development in order to minimize the costs associated with unsuccessful drugs.

Introduction of promoted technologies

A recent trend in drug development is to create new drugs that target a specific molecule identified by means of a genomic approach. Nevertheless, many drugs fail to reach clinical application, and costs associated with such unsuccessful drugs are high.

One of the major reasons for drop-out is inappropriate ADME (absorption, distribution, metabolism, and excretion) properties of candidates, resulting in low bioavailability or toxicity. It is, therefore, important to predict such problems at an early stage in the development process. GenoMembrane provides transporter vesicles as research reagents for this purpose.

Desired business for expansion

- Set-up of sales bases
  (We hope to increase sales in Europe)
- Distributorship Agreement, Agency Agreement
  (We would like to find a distributor in Europe)

Patent

US Patent No.:8,278,032 B2
Title: TRANSPORTER PROTEIN IN MAMMAL AND UTILIZATION OF THE SAME
Date of Patent: Oct.2,2012
Assignee: Genomembrane,Inc., Kanagawa(JP)
WIPO Patent Application: WO/2009/051277
Publication Date: 04/23/2009

http://www.genomembrane.com

For Contribution to better life from Gold Standard in Glycan Profiling Analysis and Competitive Cutting-Edge Culture Media for iPS

GlycoTechnica

Company Name	GlycoTechnica Ltd.
Location	Yokohama, Kanagawa, Japan
Founded in	June, 2011
Capital	USD 40,000
Representative	Harumi Takabatake

Division	Corporate Strategic Planning
Name	S. Takabatake or S. Hiruta
e-mail	basrst@glycotechnica.com
Tel	+81-45-530-4045

GlycoTechnica Ltd. is dedicated to innovating, developing and supplying forward thinking solutions in the field glycomics. GlycoTechnica provides an innovative glycan profiling analysis system, GlycoStation™ and services using lectin microarrays and washing-free evanescent-field fluorescence excitation scanners. The technology is a very useful tool for promoting life science research such as search for advanced biomarkers, quality control for protein pharmaceuticals, characterization for stem and differentiate cells.

The company is also supplying Culture Media Mesenchymal Stem Cells as a specialist and now the company announce New Type of competitive Culture Media for iPS during this year`s Bio Japan at Yokohama.

Introduction of promoted technologies

The cutting-edge culture media for iPS cells. This medium is fully bFGF/TGFβ-independent and contains only two kinds of proteins. It has already been validated with using 6 different iPS cell lines, and is easier to transfer to GMP facility comparing with existing other types of culture media.

Glycan profiling analysis system using Lectin Microarrays.
A very unique system which is able to analyze very weak biomolecular interactions with super high sensitivity and in a short time. Very powerful in the following applications, (1) new glyco-biomarker discovery and screening, (2) characterization of stem & differentiated cells, (3) infectious ability of various viruses, (4) biosimilar drugs and (5) intestinal bacteria and probiotics.

Desired business for expansion

- Export
  (We have already supplied to few customer in Europe, USA and other market, we are looking forward to aim more to Scandinavian Markets as well as UK.)
- Distributorship Agreement, Agency Agreement
  (Glyco Profiling Service Sales Agency in UK and other European Market are looked for.)
- Manufacturing service
  (We have an intention to sales base to produce our latest Culture Media in Europe.)
- Any collaborative proposals are flexibly considered.

Patent

A patent for evanescent-field fluorescence excitation scanners is held by Glycotechnica and also granted license for profiling by applying Lectin Micro Array which patent has been filed by AIST, establish higher wall to protect our overall system.
The Culture Media for iPS also achieved under license agreement with Kyoto Univ.

http://www.glycotechnica.com/english/

KANAGAWA
Leading Biotech Companies

Introduction of Government-Sponsored Bio Related Business Programs

Yokohama Kanagawa Bio Business Network

There are a number of universities and research centers in Kanagawa particularly in and around Yokohama, including sophisticated biotechnology seeds, biotech startups, and other enterprises involved in commercialization and industry support.

Our objective is to promote innovative R&D, create products in succession, activate the local economy, and help people to improve the quality of life by reinforcing the network of those who are the driving force of bio business.

https://www.yk-bio.net/en/index.html

Introduction of Important Prefectural Institutions

KIHARA MEMORIAL
YOKOHAMA FOUNDATION

To promote bio-related scholarly pursuits and industrial development, the Kihara Memorial Yokohama Foundation is engaged in diverse activities, including providing academic supports to R&D projects, dissemination of knowledge, and industry-academia-government undertakings. It also supports various businesses through activities such as administration of the Yokohama Kanagawa Bio Business Network and management and administration of facilities and installations that serve as R&D bases.

1-6 Suehiro-cho, Tsurumi-ku, Yokohama City, Kanagawa, Japan 230-0045
Phone: +81-45-502-4810 Fax: +81-45-502-9810
E-mail: yamabosi@kihara.or.jp
URL: http://kihara.or.jp/english/index_e.html